Electroacupuncture effects on trigeminal neuralgia with comorbid anxiety and depression: The role of frequency and acupoint specificity.

Researchers investigated whether electroacupuncture could help people suffering from trigeminal neuralgia—a severe facial pain condition—who also experience anxiety and depression. Using a mouse model, scientists tested different frequencies of electrical stimulation (2 Hz and 100 Hz) at two specific acupuncture points: DU20 (located on the top of the head) and ST36 (on the lower leg). The study found that electroacupuncture effectively reduced facial pain and improved mood symptoms, but the results varied depending on the frequency used and location of treatment. The higher frequency (100 Hz) provided quick pain relief and helped with feelings of despair, while the lower frequency (2 Hz) was more effective at addressing both anxiety and depression alongside pain. Importantly, the 2 Hz treatment affected a wider range of brain regions associated with mood regulation and pain processing. When comparing acupuncture points, DU20 showed superior results compared to ST36, producing stronger antidepressant and pain-relieving effects while influencing more brain activity patterns. This research suggests that for patients dealing with chronic facial pain accompanied by anxiety or depression, low-frequency electroacupuncture at specific points like DU20 may offer comprehensive relief by simultaneously addressing both physical pain and emotional distress. These findings help explain why acupuncture can be beneficial for complex conditions involving both pain and mood disorders. If you're considering electroacupuncture for trigeminal neuralgia or related conditions, consult with a licensed acupuncturist experienced in using electrical stimulation techniques.

This animal study examined electroacupuncture effects on chronic constriction injury of the infraorbital nerve (CION)-induced trigeminal neuralgia with comorbid anxiety and depression. Researchers compared 2 Hz versus 100 Hz stimulation at DU20 and ST36, using immunofluorescence staining to assess neural activity across multiple brain regions including PrL, BLA, PVN, VTA, vlPAG, and LDTgv. Key findings: 100 Hz EA provided rapid analgesia and reduced despair behavior, while 2 Hz EA demonstrated superior efficacy for both anxiety and depression, modulating broader brain networks. Point specificity analysis revealed DU20 superior to ST36, producing more extensive brain activity modulation, particularly in VTA and LDTgv regions, with enhanced antidepressant and analgesic effects. Clinical implications suggest low-frequency EA at DU20 may optimize outcomes for patients presenting with chronic orofacial pain and affective comorbidities. The study provides neurobiological evidence for frequency and point selection in treating pain-mood disorder complexes, though human trials are needed for clinical validation.